Valuation: DBV Technologies

Market Cap 56Cr 63Cr 53Cr 48Cr 90Cr 6.1TCr 91Cr 636.39Cr 246.6Cr 3.12TCr 238.08Cr 232.92Cr 10TCr P/E 2026 *
-4.33x
P/E 2027 * -13.3x
Enterprise Value 49Cr 55Cr 46Cr 42Cr 78Cr 5.28TCr 79Cr 551.15Cr 213.57Cr 2.7TCr 206.2Cr 201.72Cr 8.66TCr EV / Sales 2026 *
179x
EV / Sales 2027 * 7.16x
Free-Float
99.85%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 66 29/11/2018
Director of Finance/CFO 56 06/11/2023
Chief Operating Officer - 01/12/2023
Director TitleAgeSince
Director/Board Member 51 21/10/2015
Director/Board Member 63 21/06/2016
Director/Board Member 60 15/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 63Cr
-0.61%-3.43%+39.40%+112.31% 1,01900Cr
-1.02%-5.60%+37.67%+65.02% 62TCr
+1.11%-0.58%+11.10%+77.28% 46TCr
+0.34%-3.01%+61.21%+40.71% 36TCr
-0.95%-4.05%+21.60%+39.37% 33TCr
-1.46%-2.89%+11.84%+24.60% 27TCr
-1.35%-5.43%-4.69%+8.40% 24TCr
-1.04%-2.79%+35.52%+51.34% 22TCr
-1.87%-4.10%+30.92%+95.33% 18TCr
Average -0.21%-3.39%+27.17%+57.15% 41.08TCr
Weighted average by Cap. +0.42%-3.33%+30.52%+68.96%

Financials

2026 *2027 *
Net sales 27.19L 30.6L 25.37L 23.13L 43.62L 29Cr 44.02L 3.07Cr 1.19Cr 15Cr 1.15Cr 1.12Cr 48Cr 6.21Cr 6.98Cr 5.79Cr 5.28Cr 9.96Cr 671.47Cr 10Cr 70Cr 27Cr 343.26Cr 26Cr 26Cr 1.1TCr
Net income -17Cr -20Cr -16Cr -15Cr -28Cr -1.89TCr -28Cr -196.79Cr -76Cr -963.7Cr -74Cr -72Cr -3.09TCr -13Cr -14Cr -12Cr -11Cr -20Cr -1.36TCr -20Cr -142.47Cr -55Cr -697.65Cr -53Cr -52Cr -2.24TCr
Net Debt -7.55Cr -8.49Cr -7.04Cr -6.42Cr -12Cr -816.46Cr -12Cr -85Cr -33Cr -417.39Cr -32Cr -31Cr -1.34TCr -12Cr -13Cr -11Cr -10Cr -19Cr -1.29TCr -19Cr -134.49Cr -52Cr -658.61Cr -50Cr -49Cr -2.11TCr
Logo DBV Technologies
DBV Technologies specializes in developing solutions for diagnosing and treating food allergies (primarily to peanuts and cow's milk) using a patch (Viaskin®) that administers active ingredients into the top layers of the skin.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-